Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 11, 2012, Pages 1302-1307

  Grady, Bart P X ^a   Vanhommerig, Joost W ^a   Schinkel, Janke ^b   Weegink, Christine J ^b   Bruisten, Sylvia M ^a   Lindenburg, Catherina E A ^a   Prins, Maria ^a,b  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

HCV reinfection; Phylogenetic analysis; Relapse; Substance abuse; Treatment

Indexed keywords

NONSTRUCTURAL PROTEIN 5B; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; INJECTION; MALE; MORTALITY; PHYLOGENY; PRIORITY JOURNAL; REINFECTION; RELAPSE; SEQUENCE ANALYSIS; VIRAL CLEARANCE; VIRUS GENOME;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG USERS; FEMALE; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PATIENT CARE TEAM; PHYLOGENY; RECURRENCE; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME; URBAN HEALTH; VIRAL LOAD;

EID: 84867333329     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835702a8     Document Type: Article

References (30)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567. (Pubitemid 41196755)
2. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13:34-41.
3. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, etal. The prevalence of hepatitis Cvirus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562. (Pubitemid 29384163)
4. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18:352-358. (Pubitemid 47374507)
5. Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis Cvirus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction 2010; 105:311-318.
6. Matser A, Urbanus A, Geskus R, Kretzschmar M, Xiridou M, Buster M, et al. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107:614-623.
7. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
8. Pawlotsky JM. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis Cvirus genotype 1 infection, butwith issues still pending. Gastroenterology 2011; 140:746-754.
9. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology2002; 36 (Suppl 1):S210-S219. (Pubitemid 35253483)
10. Mehta SH,Thomas DL, Sulkowski MS, Safaein M,Vlahov D, Strathdee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis Cvirus infection among HCV-mono-infected and HIV/ HCV-co-infected injection drug users. . AIDS 2005; 19 (Suppl 3): S179-S189. (Pubitemid 41682186)
11. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93:141-147. (Pubitemid 350245718)
12. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23:23-31.
13. Grebely J, Matthews GV, Hellard M, Shaw D, van BI, Petoumenos K, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55:76-85.
14. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
15. Martin NK,Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology2012; 55:49-57.
16. Matser A, Urbanus A, Geskus R, Kretzschmar M, Xiridou M, Buster M, et al. The effect of hepatitis C treatment and HIV coinfection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107:614-623.
17. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540-1543. (Pubitemid 39518222)
18. Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008; 93:148-154. (Pubitemid 350236602)
19. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40 (Suppl 5):S336-S338. (Pubitemid 40490221)
20. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, et al. Reinfection with hepatitis Cvirus following sustained virological response in injection drug users. J Gastroenterol Hepatol 2010; 25:1281-1284.
21. Van den Hoek JA, Coutinho RA, van Haastrecht HJ, van Zadelhoff AW, Goudsmit J. Prevalence and riskfactors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988; 2:55-60. (Pubitemid 18085321)
22. Murphy DG,Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol 2007; 45:1102-1112. (Pubitemid 46626471)
23. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-973. (Pubitemid 41401136)
24. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28:2731-2739.
25. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Development Core Team; 2011.
26. Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis Cvirus (HCV) reinfection aftertreatment of sexually acquired acute HCV infection in HIV-infected men having sex with men in Amsterdam. AIDS 2011; 25:F21-F27.
27. Craxí A, Pawlotsky JM, Wedemeyer H, Bjoro K, Flisiak R, Forns X, et al. EASLclinical practice guidelines: management of hepatitis Cvirus infection. J Hepatol 2011; 55:245-264.
28. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138:315-324.
29. Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, et al. Kinetics of CD4 + and CD8 + memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003; 77:4781-4793. (Pubitemid 36402828)
30. Arends JE, van Assen S, Stek C, Wensing A, Fransen J, Schellens I, et al. Pegylated interferon-a monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C. Antivir Ther 2011; 16:979-988.